Score Overview
Explore the 2021 public Archive ranking →
Where Arrowhead Pharmaceuticals Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ARWR
2003: 89.7% · 2021: 58.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 65.45 | — |
1 Year2025-09-30 | $ 34.49 | 89.77% |
5 Years2021-09-30 | $ 62.43 | 4.84% |
10 Years2016-09-30 | $ 7.35 | 8x |
20 Years2006-09-29 | $ 49.90 | 31.16% |
30 Years1996-09-25 | $ 203.13 | -67.78% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-09-29 | 30 Years1996-09-25 |
|---|---|---|---|---|---|---|
| Price | $ 65.45 | $ 34.49 | $ 62.43 | $ 7.35 | $ 49.90 | $ 203.13 |
| Return | — | 89.77% | 4.84% | 8x | 31.16% | -67.78% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 669M | -$ 319M | $ 1.60B |
| 2025 | $ 829M | $ 919M | |
| 2024 | $ 3M | -$ 599M | $ 680M |
| 2023 | $ 240M | -$ 205M | $ 403M |
| 2022 | $ 243M | -$ 176M | $ 376M |
| 2021 | $ 138M | -$ 140M | $ 367M |
| 2020 | $ 87M | -$ 84M | $ 315M |
| 2019 | $ 168M | $ 67M | $ 258M |
| 2018 | $ 16M | -$ 54M | $ 76M |
| 2017 | $ 31M | -$ 34M | $ 65M |
| 2016 | -$ 81M | $ 85M | |
| 2015 | $ 382K | -$ 91M | $ 98M |
| 2014 | $ 175K | -$ 58M | $ 154M |
| 2013 | $ 290.27K | -$ 31M | $ 28M |
| 2012 | $ 146.88K | -$ 21M | $ 3M |
| 2011 | $ 296.14K | -$ 3M | $ 8M |
| 2010 | $ 620.1K | -$ 5M | $ 6M |
| 2009 | $ 3M | -$ 19M | $ 2M |
| 2008 | $ 1M | -$ 27M | $ 10M |
| 2007 | $ 1M | -$ 29M | $ 24M |
| 2006 | $ 595.46K | -$ 18M | $ 28M |
| 2005 | $ 590.68K | -$ 6M | $ 22M |
| 2004 | $ 196.31K | -$ 2M | $ 9M |
| 2003 | -$ 95.24K | $ 1M | |
| 2002 | $ 2.27K | -$ 246.21K | $ 18.49K |
| 2001 | $ 9.31K | -$ 185.82K | $ 271.00 |
| 2000 | $ 24.88K | -$ 137.55K | $ 1.95K |
| 1999 | $ 37K | $ 593K | $ 124.00 |
| 1998 | $ 60.38K | -$ 165.03K | $ 1.02K |
| 1997 | $ 76.59K | -$ 854.53K | $ 1.17K |
Arrowhead Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 87M to $ 829M. Revenue increased in 2 of those 5 years; net income in 0.
Across Arrowhead Pharmaceuticals Inc's full reported history, from 1997 to 2025, revenue grew from $ 76.59K to $ 829M. Revenue increased in 44% of the years measured; net income in 37%.
Arrowhead Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.
Membership
Continue ARWR’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
